Impetigo in pediatrics.

Cutis

Division of Dermatology, Children's National Medical Center, Washington, District of Columbia, USA.

Published: May 2004

Impetigo is a common skin infection in children. If not treated promptly, it can spread rapidly through a student population and become a significant health problem. Whereas uncomplicated, localized lesions typically are treated with topical mupirocin, widespread infections involving multiple pathogens require systemic treatment with a cephalosporin or a beta-lactamase-resistant antibiotic.

Download full-text PDF

Source

Publication Analysis

Top Keywords

impetigo pediatrics
4
pediatrics impetigo
4
impetigo common
4
common skin
4
skin infection
4
infection children
4
children treated
4
treated spread
4
spread rapidly
4
rapidly student
4

Similar Publications

Background: Antibiotic durations for uncomplicated skin/soft tissue infections (SSTI) often exceed the guideline-recommended 5-7 days. We assessed the effectiveness of a default duration order panel in the Electronic Health Record (EHR) to reduce long prescriptions.

Methods: Cluster randomized trial of a SSTI order panel with default antibiotic durations (implemented 12/2021), compared to a control panel (no decision support) in 14 pediatric primary care clinics.

View Article and Find Full Text PDF
Article Synopsis
  • * A total of 1200 children participated, mostly girls, and findings indicated a significant link between poor personal hygiene and higher rates of impetigo among the children.
  • * Socio-demographic elements like gender, parental education, job status, and location were found to significantly influence impetigo cases, highlighting the importance of good hygiene practices in preventing the infection.
View Article and Find Full Text PDF

Ivermectin-Based Mass Drug Administration for Scabies in Northern India: A Single-Arm Community Intervention Trial.

Open Forum Infect Dis

October 2024

Nossal Institute for Global Health, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.

Background: Scabies and impetigo cause direct health effects and contribute to severe infectious and immune-mediated complications. Ivermectin-based mass drug administration can reduce scabies and impetigo prevalence in island settings with high prevalence, but the effectiveness in moderate-prevalence settings is not known.

Methods: We conducted a single-arm, before-after community intervention trial.

View Article and Find Full Text PDF
Article Synopsis
  • Scabies and related bacterial skin infections are common in tropical and low-income areas, significantly raising healthcare costs and straining health systems.
  • The "Big SHIFT" trial in Fiji analyzed scabies and SSTIs from 2018 to 2019, aiming to estimate the healthcare costs associated with these conditions before a mass drug treatment campaign.
  • The study found that healthcare costs for scabies and SSTIs in Fiji totaled approximately $3 million annually, with an estimated cost of $3.3 per person, highlighting the economic impact and the potential benefits of prevention efforts.
View Article and Find Full Text PDF
Article Synopsis
  • Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
  • Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
  • Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!